Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$8.78
0.141.62%
At close: -
$8.60
-0.18-2.05%
After Hours: May 16, 7:23 PM EDT
Comments
Loading...
CervoMed Analyst Ratings and Price Targets | NASDAQ:CRVO | Benzinga
CervoMed Inc has a consensus price target of $25.57 based on the ratings of 8 analysts. The high is $63 issued by Brookline Capital on July 8, 2024. The low is $10 issued by D. Boral Capital on May 13, 2025. The 3 most-recent analyst ratings were released by D. Boral Capital, Chardan Capital, and D. Boral Capital on May 13, 2025, May 12, 2025, and March 26, 2025, respectively. With an average price target of $11.67 between D. Boral Capital, Chardan Capital, and D. Boral Capital, there's an implied 35.66% upside for CervoMed Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
D. Boral Capital
Chardan Capital
Roth MKM
Canaccord Genuity
Jones Trading
1calculated from analyst ratings
Analyst Ratings for CervoMed
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/13/2025 | Buy Now | 16.28% | D. Boral Capital | Jason Kolbert42% | $10 → $10 | Maintains | Buy | Get Alert |
| 05/12/2025 | Buy Now | 74.42% | Chardan Capital | Daniil Gataulin38% | $14 → $15 | Maintains | Buy | Get Alert |
| 03/26/2025 | Buy Now | 16.28% | D. Boral Capital | Jason Kolbert42% | $10 → $10 | Maintains | Buy | Get Alert |
| 03/18/2025 | Buy Now | 132.56% | Roth MKM | Boobalan Pachaiyappan54% | $15 → $20 | Maintains | Buy | Get Alert |
| 03/18/2025 | Buy Now | 144.19% | Canaccord Genuity | Sumant Kulkarni40% | $12 → $21 | Maintains | Buy | Get Alert |
| 03/18/2025 | Buy Now | 62.79% | Chardan Capital | Daniil Gataulin38% | $14 → $14 | Maintains | Buy | Get Alert |
| 03/17/2025 | Buy Now | 16.28% | D. Boral Capital | Jason Kolbert42% | $10 → $10 | Maintains | Buy | Get Alert |
| 03/13/2025 | Buy Now | 74.42% | Jones Trading | Soumit Roy33% | → $15 | Upgrade | Hold → Buy | Get Alert |
| 03/13/2025 | Buy Now | 62.79% | Chardan Capital | Daniil Gataulin38% | → $14 | Upgrade | Neutral → Buy | Get Alert |
| 03/11/2025 | Buy Now | 74.42% | Roth MKM | Boobalan Pachaiyappan54% | $7 → $15 | Maintains | Buy | Get Alert |
| 03/11/2025 | Buy Now | 16.28% | D. Boral Capital | Jason Kolbert42% | $10 → $10 | Maintains | Buy | Get Alert |
| 02/19/2025 | Buy Now | 16.28% | D. Boral Capital | Jason Kolbert42% | → $10 | Upgrade | Hold → Buy | Get Alert |
| 12/17/2024 | Buy Now | — | HC Wainwright & Co. | Raghuram Selvaraju42% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/11/2024 | Buy Now | 39.53% | Canaccord Genuity | Sumant Kulkarni40% | $65 → $12 | Maintains | Buy | Get Alert |
| 12/11/2024 | Buy Now | — | Chardan Capital | Daniil Gataulin38% | — | Downgrade | Buy → Neutral | Get Alert |
| 12/10/2024 | Buy Now | — | Jones Trading | Soumit Roy33% | — | Downgrade | Buy → Hold | Get Alert |
| 12/10/2024 | Buy Now | — | D. Boral Capital | Jason Kolbert42% | — | Downgrade | Buy → Hold | Get Alert |
| 12/05/2024 | Buy Now | 423.26% | Roth MKM | Boobalan Pachaiyappan54% | → $45 | Initiates | → Buy | Get Alert |
| 12/05/2024 | Buy Now | 388.37% | HC Wainwright & Co. | Raghuram Selvaraju42% | → $42 | Initiates | → Buy | Get Alert |
| 11/27/2024 | Buy Now | 295.35% | D. Boral Capital | Jason Kolbert42% | $34 → $34 | Maintains | Buy | Get Alert |
| 11/18/2024 | Buy Now | 295.35% | D. Boral Capital | Jason Kolbert42% | → $34 | Initiates | → Buy | Get Alert |
| 11/14/2024 | Buy Now | 539.53% | Chardan Capital | Daniil Gataulin38% | $55 → $55 | Maintains | Buy | Get Alert |
| 09/18/2024 | Buy Now | 539.53% | Chardan Capital | Daniil Gataulin38% | → $55 | Initiates | → Buy | Get Alert |
| 07/26/2024 | Buy Now | 306.98% | Morgan Stanley | Jeffrey Hung49% | → $35 | Initiates | → Overweight | Get Alert |
| 07/25/2024 | Buy Now | 655.81% | Canaccord Genuity | Sumant Kulkarni40% | $65 → $65 | Maintains | Buy | Get Alert |
| 07/08/2024 | Buy Now | 632.56% | Brookline Capital | Tyler Bussian23% | → $63 | Initiates | → Buy | Get Alert |
| 05/29/2024 | Buy Now | 713.95% | Jones Trading | Soumit Roy33% | → $70 | Initiates | → Buy | Get Alert |
| 04/08/2024 | Buy Now | 655.81% | Canaccord Genuity | Sumant Kulkarni40% | $50 → $65 | Maintains | Buy | Get Alert |
| 02/15/2024 | Buy Now | 481.4% | Canaccord Genuity | Sumant Kulkarni40% | → $50 | Initiates | → Buy | Get Alert |
FAQ
What is the target price for CervoMed (CRVO) stock?
The latest price target for CervoMed (NASDAQ:CRVO) was reported by D. Boral Capital on May 13, 2025. The analyst firm set a price target for $10.00 expecting CRVO to rise to within 12 months (a possible 16.28% upside). 27 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for CervoMed (CRVO)?
The latest analyst rating for CervoMed (NASDAQ:CRVO) was provided by D. Boral Capital, and CervoMed maintained their buy rating.
When was the last upgrade for CervoMed (CRVO)?
The last upgrade for CervoMed Inc happened on March 13, 2025 when Jones Trading raised their price target to $15. Jones Trading previously had a hold for CervoMed Inc.
When was the last downgrade for CervoMed (CRVO)?
The last downgrade for CervoMed Inc happened on December 17, 2024 when HC Wainwright & Co. changed their price target from N/A to N/A for CervoMed Inc.
When is the next analyst rating going to be posted or updated for CervoMed (CRVO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of CervoMed, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for CervoMed was filed on May 13, 2025 so you should expect the next rating to be made available sometime around May 13, 2026.
Is the Analyst Rating CervoMed (CRVO) correct?
While ratings are subjective and will change, the latest CervoMed (CRVO) rating was a maintained with a price target of $10.00 to $10.00. The current price CervoMed (CRVO) is trading at is $8.60, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
